All In Biotech

Drug Trial Radar · NCT04333108

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Phase 3 Study to Compare Oral Masitinib to Placebo in Treatment of Patients With Smouldering or Indolent Severe Systemic Mastocytosis, Unresponsive to Optimal Symptomatic Treatment

Last checked: Nov 20, 2026Latest source record: May 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

140

Planned (sponsor's estimate)

Start

Jul 1, 2020

Primary completion

Dec 2024

Study completion Jun 2025

Sponsor

Lead sponsor
AB ScienceIndustry
Sponsor type
Industry
First posted
Apr 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients suffering from smouldering or indolent systemic mastocytosis with severe symptoms of mast cell mediator release, unresponsive to optimal symptomatic treatment.

Conditions

  • Indolent Systemic Mastocytosis

Interventions

  • MasitinibDrug

    Masitinib 6 mg/kg/day

  • PlaceboOther

    Matching placebo

  • Best Supportive CareOther

    Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglycate, antidepressants, leukotriene antagonists and corticosteroids.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative response (3R75%)Time frame: 24 weeks

Locations

17 sites in 8 countries. Site status is shown where the registry gives one.

  • Centre Hospitalier Universitaire d'Amiens

    Amiens, France · Recruiting

  • Hospital Jean-Minjoz

    Besançon, France · Recruiting

  • Grenoble University Hospital

    Grenoble, France · Recruiting

  • Hospital Claude Huriez

    Lille, France · Recruiting

  • Marseille University Hospital Timone

    Marseille, France · Recruiting

  • Centre de référence de Mastocytose (CEREMAST)

    Paris, France · Recruiting

  • Poitiers University Hospital

    Poitiers, France · Recruiting

  • Centre Hospitalier Universitaire

    Toulouse, France · Recruiting

  • University Hospital Charité

    Berlin, Germany · Not yet recruiting

  • Erasmus University Medical Center

    Rotterdam, Netherlands · Recruiting

  • Medical University of Gdańsk

    Gdansk, Poland · Recruiting

  • The University Hospital in Krakow (Szpital Uniwersytecki w Krakowie)

    Krakow, Poland · Recruiting

  • University Hospital in Bucharest (Spitalul Universitar de Urgență București)

    Bucharest, Romania · Recruiting

  • Almazov National Medical Research Centre

    Saint Petersburg, Russia · Recruiting

  • Dnipropetrovsk Clinical Association of Emergency Medical Care of Dnipropetrovsk Regional

    Dnipro, Ukraine · Recruiting

  • Private Enterprise Private Manufacturing Company Acinus

    Poltava, Ukraine · Recruiting

  • Guy's and St Thomas' NHS Foundation Trust

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.